-
Bristol-Myers Squibb Reports Q4 EPS of $.47 vs. $.48
Thursday, January 27, 2011 - 8:31am | 119Bristol-Myers Squibb Company (NYSE: BMY) today announced solid results for the fourth quarter of 2010. Bristol-Myers Squibb posted fourth quarter 2010 net sales of $5.1 billion. U.S. health care reform had a 1.5% negative effect on net sales in the fourth quarter. The Company reported fourth...
-
Eli Lilly Beats EPS Estimates By 1 Cent (LLY)
Thursday, January 27, 2011 - 8:03am | 261Indianapolis, Indiana-based Eli Lilly and Company (NYSE: LLY) announced on Thursday morning that it beat consensus Wall Street estimates. Eli Lilly and Company reported that its 4th quarter net income climbed 28% to $1.17 billion, or $1.05 per share, up from $915.4 million, or 83 cents per share, a...
-
Citigroup Downs ABT To Sell
Thursday, January 27, 2011 - 7:02am | 49Analysts at Citigroup downgrade Abbott Laboratories (NYSE: ABT) from “hold” to “sell.” The target price for ABT has been lowered from $48 to $44. ABT shares dropped 2.52% to close at $46.75 yesterday. More Analyst Ratings here
-
Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)
Thursday, January 27, 2011 - 4:44am | 471Caterpillar (NYSE: CAT) is expected to report its Q4 earnings at $1.27 per share on revenue of $11.63 billion. Microsoft Corp (NASDAQ: MSFT) is projected to report its Q2 EPS at $0.68 on revenue of $19.14 billion. Procter & Gamble Co (NYSE: PG) is estimated to post its Q2 earnings of $1.10 per...
-
Guest Post: Set the Bar High
Wednesday, January 26, 2011 - 8:35pm | 2319By Vitaliy N. Katsenelson, CFA The world today is riddled with unique economic, political, and demographic risks. Finding attractively priced assets that will perform well in spite of these challenges is excruciatingly difficult. For investors, though, one segment of the market – the highest-...
-
Guest Post: Set the Bar High
Wednesday, January 26, 2011 - 8:35pm | 2237By Vitaliy N. Katsenelson, CFA The world today is riddled with unique economic, political, and demographic risks. Finding attractively priced assets that will perform well in spite of these challenges is excruciatingly difficult. For investors, though, one segment of the market – the highest-...
-
The Ups and Downs of Flying
Wednesday, January 26, 2011 - 4:01pm | 2185By Vitaliy Katsenelson On Monday January 31st, my brother Alex and I are flying to the VALUEx conference in Zurich/Davos, then on February 7th I am giving a half-day seminar at the Value Investing Center in Frankfurt. I am not going to be writing another book for a long, long time (if ever...
-
Earnings Preview: Bristol-Myers - Analyst Blog
Wednesday, January 26, 2011 - 2:01pm | 726Bristol-Myers Squibb Company (BMY) is all set to announce its fourth quarter and full year 2010 results on January 27, 2011 before the opening bell. The Zacks Consensus Estimate for the fourth quarter is 48 cents, representing a year-over-year increase of 2.1%. The Zacks Consensus Estimate for...
-
More Upside Seen On Fil-Estate Land (LND) Part 2
Wednesday, January 26, 2011 - 1:36pm | 727Fil-Estate Land (LND) hit the stock market headlines once again yesterday when it surged by 9.63% from opening of PHP 2.23 to a closing of PHP 2.39. Now, a lot of you might be asking if there is still some more upside on this issue. remember that back in December 23, 2010, LND...
-
Teva to Acquire Corporación Infarmasa
Wednesday, January 26, 2011 - 1:30pm | 97Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments. The Peruvian pharmaceutical market grew at a CAGR of 12% from 2005 to 2010 and is expected to reach $...
-
Earnings Preview: Bristol-Myers - Analyst Blog
Wednesday, January 26, 2011 - 1:15pm | 726Bristol-Myers Squibb Company (BMY) is all set to announce its fourth quarter and full year 2010 results on January 27, 2011 before the opening bell. The Zacks Consensus Estimate for the fourth quarter is 48 cents, representing a year-over-year increase of 2.1%. The Zacks Consensus Estimate for...
-
Teva Flying On Drug Launch (TEVA)
Wednesday, January 26, 2011 - 12:34pm | 114Shares of Teva Pharmaceuticals (NASDAQ: TEVA) are rising on heavy volume on Wednesday after the company announced the commercial launch of Gemcitabine HCI for Injection in 200mg and 1g single dose vials. The drug is the generic version of Gemzar. Under the agreement, APP Pharmaceuticals, Inc. will...
-
J.P. Morgan Assigns Johnson & Johnson Neutral Rating (JNJ)
Wednesday, January 26, 2011 - 11:49am | 153J.P. Morgan assigned Johnson & Johnson (NYSE: JNJ) a Neutral rating in a research report published today. J.P. Morgan has a price target of $69 for Johnson & Johnson. In the report, J.P. Morgan states, "J&J has weathered a difficult couple of years, facing challenges on multiple fronts...
-
Perrigo Company Announces Dividend of $.07
Wednesday, January 26, 2011 - 11:17am | 35Perrigo Company (Nasdaq: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on March 15, 2011 to shareholders of record on February 25, 2011.
-
Abbott Labs Tops 4Q Estimates - Analyst Blog
Wednesday, January 26, 2011 - 11:01am | 898Abbott Laboratories (ABT) reported fourth quarter earnings of $1.30 per share, a penny above the Zacks Consensus Estimate and within the guidance range provided by the company. Earnings increased 10.2% from the year-ago period. Higher revenues helped drive results. However, including one-time...